Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: To evaluate the feasibility of producing lifileucel using tumor samples obtained before (Cohort 3D) or during (Cohort 3E) frontline platinum doublet chemotherapy and pembrolizumab in patients with Stage IV NSCLC. After: Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: Percentage of patients for whom lifileucel is successfully manufactured and meets release specification.
Participant count type changed
Before: Estimated. After: Actual.
Enrollment · participant count changed
Before: 245 participants (planned). After: 225 participants (actual).
Completion date type changed
Before: Estimated. After: Actual.
Primary completion date changed
Before: 9 Aug 2029. After: 20 Feb 2026.
Recruitment status changed
Before: Recruiting. After: Terminated.